Ranking Invest

BELLUS Health Inc.

Segmento: Healthcare BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

Indicadores Básicos

Valor de Mercado

$ 1.87 Bi

IVR

0.51

IVR2

-0.14

Índices de Previsibilidade

Faturamento

1.05

Lucro

0.27

Margem

0.44

Índices de Tendência

Faturamento

6.89

Lucro

-9.67

Margem

-2.52

Índices de Endividamento

DIV/PAT

-0.19

DIV/L4T

2.11

Dívida Líquida

-$ 228.64 Mi

Patrimônio Líquido

$ 1.19 Bi

L4T

-$ 108.19 Mi

MM4T

-322871.84%

Dívidas
Dividendos
Cotação: $14.75

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre